VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors.
VM 26, a semisynthetic podophyllin derivative (4-demethyl-epipodo-phyllotoxin-beta-d-thenylidine glucoside) has been tested in 67 patients with urinary bladder tumors. In 25 patients with stage T 1 significant prolongation of the disease-free interval was reached. In 25 cases with state T 3-4, the effect of VM 26 was not favorable.
D002291:Carcinoma, Papillary / Q000188:drug therapy; D006801:Humans; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012008:Recurrence; D012075:Remission, Spontaneous; D013713:Teniposide / Q000627:therapeutic use*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D013713:Teniposide; D011034:Podophyllotoxin